RGDV

• Description:

  RGDV is a platelet aggregation inhibitor. RGDV inhibits platelet-dependent thrombus formation. RGDV is used for tumor recognition via the targeting effect[1][2].

• UNSPSC:

  12352209

• Target:

  Others

• Type:

  Peptides

• Related Pathways:

  Others

• Applications:

  Cancer-programmed cell death

• Field of Research:

  Cancer

• Assay Protocol:

  https://www.medchemexpress.com/rgdv.html

• Solubility:

  10 mM in DMSO

• Smiles:

  O=C (NCC (N[C@@H] (CC (O) =O) C (N[C@@H] (C (C) C) C (O) =O) =O) =O) [C@H] (CCCNC (N) =N) N

• Molecular Formula:

  C17H31N7O7

• Molecular Weight:

  445.47

• References & Citations:

  [1]Cadroy Y, et, al. RGDV peptide selectively inhibits platelet-dependent thrombus formation in vivo. Studies using a baboon model. J Clin Invest. 1989 Sep;84 (3) :939-44.|[2]Wang F, et, al. Preparation and biological evaluation of tumor-specific Ara-C liposomal preparations containing RGDV motif. J Pharm Sci. 2012 Dec;101 (12) :4559-68.

• Shipping Conditions:

  Room temperature

• Scientific Category:

  Peptides

• Clinical Information:

  No Development Reported

• CAS Number:

  93674-99-8